|
Título:
|
Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis
|
|
Autores:
|
Arroyo, Gianfranco ;
Bustos, Javier A. ;
Lescano, Andres G. ;
Gonzales, Isidro ;
Saavedra, Herbert ;
Rodriguez, Silvia ;
Pretell, E. Javier ;
Bonato, Pierina S. ;
Lanchote, Vera L. ;
Takayanagui, Osvaldo M. ;
Horton, John ;
Gonzalez, Armando E. ;
Gilman, Robert H. ;
Garcia, Hector H.
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Oxford University Press, 2019-07-04T16:59:18Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
Background: Albendazole is the drug of choice for the treatment of parenchymal neurocysticercosis, although its efficacy is suboptimal. Plasma levels of albendazole sulfoxide (ASOX), the active metabolite of albendazole, are highly variable among patients. We hypothesized that high ASOX plasma levels during albendazole therapy may be associated with an increased antiparasitic efficacy. Methods: ASOX plasma levels were measured at treatment day 7 in 118 patients with parenchymal neurocysticercosis enrolled in a trial of antiparasitic efficacy. The relationships between increasing ASOX plasma levels with (1) the proportion of cysts resolved, and (2) the proportion of patients with complete cyst clearance (evaluated by brain MRI 6 months after treatment) were assessed. Results: There was a trend towards a higher proportion of cysts resolved and a higher proportion of patients cured with increasing quartiles of ASOX plasma levels. In patients with >/=3 brain cysts, the regression analysis adjusted by the concomitant administration of PZQ showed a 2-fold increase in the proportion of cysts resolved (RR 1.98, 95% CI 1.01-3.89, p = 0.048) and 2.5-fold increase in the proportion of patients cured (RR 2.45, 95% CI 0.94-6.36, p = 0.067) when comparing ASOX levels in the highest versus the lowest quartile. In patients with
|
|
En línea:
|
http://doi.org/10.1093/cid/ciz085
|
